Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Oncolytics Biotech Funds Pelareorep’s Development with a Share Purchase Agreement in Partnership with Alumni Capital

April 15, 2025

Edity Therapeutics and Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors

April 8, 2025

Boehringer Ingelheim strengthens ADC portfolio with new NBE Therapeutics R&D center in Basel 

April 8, 2025

BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched

April 8, 2025

Bayer and Puhe BioPharma enter into global license agreement for Ph 1 PRMT5 inhibitor

April 2, 2025

Relmada Therapeutics Licenses Ph 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma

April 2, 2025

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933

March 26, 2025

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Therapeutic Antibodies

March 26, 2025

Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

March 26, 2025

2seventy bio Enters into Definitive Agreement to be Acquired by BMS

March 18, 2025

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets

March 18, 2025

iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors

March 18, 2025

AstraZeneca to acquire EsoBiotec to advance cell therapy ambition

March 18, 2025

Taiho Pharmaceutical to Acquire Next-Gen ADC Drug Discovery Company Araris Biotech

March 18, 2025

Johnson & Johnson to not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38

March 18, 2025

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for HNSCC

March 18, 2025

BioCity Biopharmaceutics Announces Clinical Collaboration to Evaluate BC3195 + KEYTRUDA combination in Patients with Locally Advanced or Metastatic Solid Tumors

March 18, 2025

SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113

March 18, 2025

ImmunoPrecise Antibodies and a Global Biotechnology Company Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics

March 18, 2025

Head and Neck Cancer Registration Study Protocol Clears FDA Review; in Talks with Potential Partners Interested in Commercialization of Multikine

March 18, 2025

Molecular Partners – Novartis collaboration to develop DARPin-conjugated radioligands for cancer comes to an end

March 11, 2025

Jazz Pharmaceuticals to Acquire Chimerix

March 11, 2025

Sun Pharma to Acquire Checkpoint Therapeutics

March 11, 2025

Zymeworks Announces Achievement of $14M Milestone from GSK Collaboration

March 11, 2025

Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen

March 11, 2025
Page1 Page2 Page3 Page4 … Page26

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.